#China #Shanghai #Q3 2025 #Hengrui Pharma #oncology studies

Hengrui Pharma Shows Robust Growth in Q3 2025

Hengrui Pharma, the renowned biopharmaceutical company, has recently announced an impressive financial performance for the first three quarters of 2025, highlighting its commitment to innovation and global expansion. The company recorded a revenue of RMB 23.20 billion, reflecting a significant year-on-year increase of 14.85%. This revenue growth is complemented by a notable rise in net profit, attributable to shareholders, which surged by 24.50% to RMB 5.75 billion compared to the same period last year.

During this period, Hengrui Pharma achieved several milestones in its research and development efforts. The company received approval for one new molecular entity (NME) in China and submitted eight new drug applications (NDAs), along with being granted 48 approvals for clinical trials. Notably, four of their programs were recognized with breakthrough therapy designations, underscoring the potential impact of their innovative therapies in the healthcare sector.

One of the standout developments from Hengrui's pipeline is the GLP-1/GIP dual agonist, HRS9531, which demonstrated positive top-line results in a Phase III trial aimed at weight management. This advancement positions Hengrui well in the competitive metabolic therapy market, showcasing their ability to deliver effective solutions to patients.

The company also made significant strides in oncology, presenting an impressive compilation of 46 studies at the European Society for Medical Oncology (ESMO) 2025 congress held in Berlin. Among these, there were nine oral presentations, with one study published in the prestigious journal The Lancet, reflecting Hengrui's rising status in global oncology research and their commitment to advancing cancer treatment.

In a strategic bid to enhance its reach and capabilities, Hengrui Pharma entered into three licensing agreements with multinational partners during the third quarter. Collectively, these partnerships promise a potential transaction value exceeding $10 billion, further solidifying Hengrui's position in the global pharmaceutical landscape.

Looking ahead, Hengrui Pharma remains focused on driving forward its homegrown R&D innovation. The leadership team emphasizes the company's commitment to strengthening its global execution through continuous clinical development and strategic partnerships. By doing so, Hengrui aims to deliver cutting-edge therapies that significantly improve the lives of patients worldwide.

As the pharmaceutical industry continues to evolve, Hengrui Pharma's proactive approach and dedication to research and development signal a bright future for the company and its mission to meet the healthcare needs of a global population. The developments showcased in Q3 2025 not only highlight Hengrui's financial robustness but also its strong commitment to innovation in the biopharmaceutical sector.